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Background   The in vivo pharmacokinetics of genta-
mycin-loaded collagen ﬂeeces in humans have not been 
described in the current literature. We therefore ana-
lyzed in vivo pharmacokinetics of these ﬂeeces when 
used in the treatment of periprosthetic infections.
Patients and methods   Gentamycin concentrations 
were measured in 19 consecutive patients with an acute 
periprosthetic infection. Each patient received 2–5 
ﬂeeces (130 mg gentamycin/ﬂeece). 
Results   Initially, the blood concentration increased 
to 3.2–7.2 mg/L, depending on the number of ﬂeeces 
that were applied. The serum peak concentrations 
resulted in peak/MIC ratios of 2.5–36 for P. aeruginosa, 
S. aureus, and Klebsiella spp. Subsequently, the serum 
values decreased almost linearly below 0.3 mg/L in 18 to 
62 hours. After 24 hours, the serum levels of gentamicin 
dropped below 2 mg/L, the toxicity threshold.
Interpretation   The application of 2 to 5 130-mg 
gentamycin-loaded collagen ﬂeeces may be useful as an 
adjuvant treatment for implant-related infections, since 
no toxic concentrations were measured 24 hours post-
operatively.   
■
In early postoperative deep hip prosthesis infec-
tions, according to the criteria of Smyth and 
Emmerson (2000), debridement, irrigation drain-
age, and systemic high-dose antibiotics (amino-
glycosides) while retaining the prosthesis may be 
effective if the treatment is initiated within 24–36 
hours of the onset signs of infection (Buchholz et 
al. 1981, Anttipoika et al. 1990). In infected pros-
theses, bacteria adhere to the surfaces of implants, 
producing a bioﬁlm that has a protective effect 
against many antimicrobial agents because of their 
reduced metabolic activity (Brown et al. 1990, 
Habash et al. 1999). As a result, the minimum 
inhibitory concentration (MIC) is increased. Local 
antibiotics can be used to achieve a high concentra-
tion (up to 1,000 fold) at the local site (Diefenbeck 
et al. 2006). 
Aminoglycosides (e.g. gentamicin) have a 
narrow therapeutic index. After intravenous 
administration, bioavailability is 100% and peak 
serum concentrations occur at the end of a 30-
min infusion. After intramuscular administration, 
bioavailability is also 100% and peak serum con-
centrations occur after 30–90 min. Gentamicin 
administered intravenously has a half-life of 2 
(0.5–3) h in adults. The therapeutic serum level is 
in the 4–10 mg/L range. Within 24 h, 30–100% 
of the gentamicin is eliminated by renal excre-
tion in unchanged form. Gentamicin accumulates 
in the lysosomes of kidney proximal tubular cells 
and causes apoptosis at clinically relevant doses 
(Servais et al. 2006). Intravenous administration 
at levels of more than 2 mg/L is generally consid-
ered to be toxic for the patient, and is known to 
have adverse systemic effects such as ototoxicity 
and nephrotoxicity (Siber et al. 1975, Isselbacher 
et al. 1994). 
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In a kinetic release model, 95% of gentamicin 
was found to be released from collagen ﬂeeces after 
1.5 hours, compared to only 8% from poly(methyl 
methacrylate) (PMMA) beads (Sørensen et al. 
1990). In local application, this carrier substance 
results in initially high local gentamicin concentra-
tions for the ﬁrst 4 hours, falling over a maximum 
of 4 days (Mehta et al. 1996, Wachol-Drewek et al. 
1996). Although not controlled and not randomized, 
clinical results of the application of gentamicin-
loaded collagen ﬂeeces indicate that they appear to 
be of value for treatment of osteomyelitis (Diefen-
beck et al. 2006). There are no data available in the 
drug information of the Royal Dutch Association 
for the Advancement of Pharmacy on the in vivo 
pharmacokinetics of this locally administered gen-
tamicin-loaded collagen ﬂeece in humans; nor have 
we found any such information in the literature.
We analyzed the in vivo pharmacokinetics of a 
gentamicin-loaded collagen ﬂeece in a cohort of 
acute periprosthetic infections.
Patients and methods
From 1998 to 2004, 19 patients with a hip or knee 
arthroplasty endured an acute surgical site infec-
tion. They were included in this study after obtain-
ing written informed consent. The treatment con-
sidered of open surgical debridement, pulsative irri-
gation, retention of the prosthesis and application 
of two or more gentamicin-loaded ﬂeeces (Gara-
col; Schering-Plough, Maarssen, the Netherlands) 
in the artiﬁcial jointe before closing the wound 
(Table 1). An acute (deep or superﬁcial) surgical 
site infection (SSI) was diagnosed within 1 year 
after implanttion of the prosthesis, according to the 
criteria of Smyth and Emmerson (2000). 
Two or more gentamicin-loaded collagen ﬂeeces 
in combination with surgical debridement, irriga-
tion while retaining the prosthesis were applied.  In 
addition, empirical systemic administration of anti-
biotics other than gentamicin was started and subse-
quently adjusted to the sensitivity of the microbial 
species involved. The collagen ﬂeece measures 10 
× 10 × 0.5 cm and contains an equivalent of 130 mg 
gentamicin sulfate. It is a bovine collagen, which is 
fully biodegradable. Application of a maximum of 
5 ﬂeeces in case of osseous infections is advised 
by the manufacturer. The number of sponges used 
was decided peroperatively by the surgeon, based 
on the extent of the infected tissue. No drainage 
system was used. No additional systemic gentami-
cin was administered postoperatively.
Cultures were taken before debridement. Inﬂam-
matory parameters, creatinine levels, and the gen-
tamicin serum concentrations were measured post-
operatively at 6, 12, 18, and 24 h and after each 
consecutive 24-h period until gentamicin was no 
longer detectable. Serum gentamicin was mea-
sured by ﬂuorescence polarization immunoassay 
(AxSYM analyzer; Abbott Laboratories, Diag-
nostics Division, Abbott Park, IL) according to 
the instructions for gentamicin provided with the 
instrument. The sensitivity, deﬁned as the lowest 
measurable concentration that can be distinguished 
from zero with 95% conﬁdence, was 0.30 µg/mL. 
The variation coefﬁcients between runs were less 
than 7% for concentrations between 1.0 and 8.0 
mg/L. As a toxicity reference, 2 mg/L gentamicin 
in serum was used. Creatinine clearance was cal-
culated according to the Cockcroft-Gault formula 
(1976). In order to demonstrate the effectiveness 
of the concentration of gentamicin measured, the 
measured peak serum concentration was divided 
by the minimum inhibitory concentration for each 
microorganism cultured.
Table 1. Characteristics of the 19 patients with infected 
arthroplasties
Gender  
 Male    2 
 Female   1 
Age at operation, years (range) 73 (48–83)
Weight, kg (range) 77 (62–98)
Height, cm (range) 163 (148–178)
Body mass index 30 (19–41)
Infected prosthesis (n) 
 Primary total hip arthoplasty 14
 Revision total hip arthroplasty   3
 Total knee arthroplasty   1
 Hemiarthroplasty   1
ASA a classiﬁcation 
 1   1
 2   8
 3   8
 4   0
a ASA: American Society of Anesthesiologists physical 
status classiﬁcation (Owens et al. 1978).
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number of ﬂeeces applied and subsequent genta-
micin peak serum concentrations. There was an 
inverted relation between weight and the peak 
serum concentration of gentamicin in this series (p 
Table 2. Observations
Case no No. of  Gentamicin Peak serum Creatinine 
 sponges used   gentamicin   clearance
  (mg)  concentration  (mg/L)
   (mL/min)
 1 3.5  455  7.1    50
 2 3 390 NR a NR
 3 3 390 3.7 121
 4 3 390 4.8   78
 5 3 390 7.2 NR
 6 4 520 4.5   68
 7 2 260 1.0   62
 8 4 520 3.2   51
 9 3 390 2.7   51
 10 4 520 5.7   64
 11 5  650  0.6    99
 12 5  650  2.4    68
 13 5  650  3.0    68
 14  5  650  6.9    49
 15  2  260  4.7    89
 16  2  260  1.4  106
 17  5  650  6.4    41
 18  3  390  6.8    53
 19  4  520  NR    34
Average (SD)  3.6 (1.0)  469 (138)  4.2 (2.2)    68 (24)
a NR: not reported.
Results (Table 2)
Initially, the serum concentration 
increased to 3.2–7.2 mg/L in 4.5 to 6 
h. The values subsequently decreased 
almost linearly below 0.3 mg/L in 18 
to 62 h. After 24 h, the gentamicin 
levels dropped below the 2 mg/L refer-
ence toxicity concentration in all cases 
(Figure 1).
 The culture specimens contained P. 
aeruginosa, S. aureus and/or Klebsiella 
spp. The peak concentrations measured 
in the serum gave peak/MIC ratios of 
3.5:1 to 8:1 for P. aeruginosa (MIC 0.9 
mg/L), 16:1 to 36:1 for S. aureus (MIC 
0.2 mg/L) and 2.3:1 to 5.1:1 for Kleb-
siella spp. (MIC 1.4 mg/L), which are 
representative values for members of 
the Enterobacteriaceae family (Lorent-
zen et al. 1996). Apart from 2 patients 
with reduced clearances (cases 17 and 
19 in Table 1), all patients had renal 
clearances within the normal range. 
There was no association between the 
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Pearson rho correlation analysis and descriptives 
were performed using SPSS software, version 
15.0.
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< 0.001) (Figure 3), which is in accordance with 
the formula described by Cockcroft and Gault 
(1976) for calculation of renal clearance. 
Discussion
We found that the gentamicin serum levels 
decreased to non-toxic levels 1 day after applica-
tion of gentamicin-loaded ﬂeeces. Authors of in 
vitro studies of gentamicin-loaded ﬂeeces (Gara-
col) have reported a quick release of gentamicin in 
the ﬁrst 6 h after application (Blanc 1992).
Although there is quick release of gentamicin 
from its carrier, the bioavailability of gentamicin 
from collagen ﬂeeces is different from that after 
intramuscular administration. The release from 
collagen appears to accelerate in a medium or envi-
ronment with a rising pH (Firsov 1987). At the sur-
gical site, the pH is lower than physiological pH, 
suggesting a slower release in vivo than in vitro 
(Sorensen et al. 1990, Blanc 1992). Because of 
these differences in pharmacokinetic behavior of 
the drug, a comparison between local application 
of gentamicin and intramuscular inﬁltration is war-
ranted. Several authors have reported bactericidal 
gentamicin levels higher than 300 mg/L at the sur-
gical site after application of gentamycin ﬂeeces 
(Young and Hewitt, 1973, Von Hasselbach 1989, 
Jorgensen et al. 1991, Wernet et al. 1992, Lethsch 
et al. 1993). These high levels (ranging from 381 to 
5,117 mg/L) were maintained for 2  up to 5 days, 
which suggests that there is slower release than 
would be predicted by in vitro results (Jorgensen 
et al. 1991, Wernet et al. 1992). Resorption and 
diffusion into the blood vessels and the degree of 
vascularization are the immeasurable determining 
factors of the bioavailability of gentamicin from 
collagen ﬂeeces. After intravenous administration, 
bactericidal gentamicin levels higher than 300 mg/
L for gentamicin-resistant microorganisms (Von 
Hasselbach 1989) cannot be achieved at the surgi-
cal site within a few hours and then maintained for 
24 h without serious adverse effects such as oto-
toxicity and nephrotoxicity. Whereas bactericidal 
concentrations were achieved locally at the surgi-
cal site with Garacol (Young and Hewitt 1973, Von 
Hasselbach 1989, Jorgensen et al. 1991, Wernet et 
al. 1992, Lethsch et al. 1993), the serum levels of 
gentamicin were found to decrease to the non-toxic 
range within 1 day without any risk of adverse 
effects. Also, in 20 patients treated with netilmi-
cin-impregnated locally impacted cancellous bone 
in hip or knee revision procedures, extremely high 
concentrations of the antibiotic were recorded in 
the wound drainage on the ﬁrst days after surgery 
without any adverse systemic effects (Witsø et al. 
2004).
The initially very high bactericidal concentra-
tions at the surgical site in the ﬁrst hours after 
administration favor the use of gentamicin-loaded 
Figure 2. The pharmacokinetics of local deliverers of gen-
tamicin.
a Gentamicin concentration that is bactericidal in the case 
of resistant pathogens (300 mg/L).
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Figure 3. Plots of weight and gentamicin peak concentration 
for each patient (plotted in order of increasing weight).
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sponges rather than gentamicin-loaded PMMA 
beads, which do not give these levels (Walenkamp 
1989, Walenkamp and Karsemaker 1998). PMMA 
beads have their maximum serum concentrations 
after 1 day, which do not reach toxic levels. In vitro 
Garacol has it peak serum concentration within 6 h 
of administration, and the toxic serum level falls to 
less than 2 mg/L within 24 h. Conventional 7-mm 
PMMA beads slowly release gentamicin, result-
ing in exudate levels of approximately 30 mg/L 
within the ﬁrst day postoperatively, and provide 
local concentrations of approximately 5 mg/L for 
2–3 weeks. These levels are well above the con-
centrations of 4 mg/L necessary to inhibit sensitive 
and moderately sensitive pathogens (Young and 
Hewitt 1973), whereas resistant microbes will not 
be affected. The effect in tissue approximately 1–2 
mm away from the implant, where the concentra-
tion will be much lower, is still unclear (Wahlig 
et al. 1978, Walenkamp 1989, Miclau et al. 1993). 
The 3-mm × 5-mm mini PMMA beads have a 
higher and earlier peak serum concentration than 
the conventional 7-mm PMMA beads, but still no 
bactericidal concentrations at surgical site are mea-
sured for resistant microbes for either (Walenkamp 
1989). They do have the same steady state of 5 
mg/L at the surgical site for several weeks (Figure 
2). The disadvantage of beads is that they must be 
removed; otherwise they themselves will be an 
infection site after 2–3 weeks (Neut et al. 2001). 
When they are mixed with acrylic bone cement, 
in vitro measurements have demonstrated a high 
but rapidly falling antibiotic level within the ﬁrst 
postoperative week, followed by a slowly decreas-
ing concentration, still with some inhibitory effect 
after 1 year (Bálint et al. 2004). In vivo studies 
have shown high bactericidal concentrations of 
gentamicin in wound exudates for 2 to 5 days with-
out toxic serum concentrations (Wernet et al. 1992, 
Letsch et al. 1993). 
In contrast, a subsequent study conducted in our 
hospital demonstrated toxic serum concentrations 
in 7 of 12 patients, resulting in a persistent renal 
clearance failure in 3 patients (Swieringa and Tulp 
2005. In this study group, 4–6 gentamicin-loaded 
ﬂeeces were applied and mean toxic levels of 4.2 
mg/L were measured up to 10 days after appli-
cation. In the present study, the application was 
reduced to 2–5 sponges; all cases showed a reduced 
gentamicin level below the toxic concentration of 2 
mg/L, while a transiently reduced creatinine clear-
ance was observed in only two patients. The dif-
ference can be explained by the reduced number 
of ﬂeeces, which accounts for a relatively shorter 
period of toxic concentrations, but no relationship 
was found between the number of ﬂeeces included 
and serum level of gentamicin. On the other hand, 
this can be explained by some surgery-related fac-
tors, for example as a function of the size of the 
surface area of the surgical wound after the radical 
debridement or quality of bleeding cease. The low 
number of patients may also have had an inﬂuence 
on the results. 
Comparison of Garacol with Septocoll was 
done in a cohort of 40 patients with contaminated 
wounds. There was a peak value in serum in the 
Sulmycin (also known as Garacol) group (0.349 
mg/L) that was almost three times higher than in 
the EMD 53155 (later known as Septocoll) group 
(0.977 mg/L); after 24 h, the curves came increas-
ingly into line (Walenkamp and Karsemaker 
1998). After 72 h, the serum concentrations in 
both cases were below 0.01 mg/L. Although both 
groups reached concentrations between 800 and 
5,000 mg/L in wound secretions, after two days 
the values in the Sulmycin group were subject to 
greater ﬂuctuation than those in the EMD 53155 
group. Moore et al. (1987) found that the peak/MIC 
ratio was signiﬁcantly higher in patients with good 
clinical responses to therapy than in patients with 
poor clinical responses. Two years later, Leggett et 
al. (1989) reported that for a murine pneumonitis 
and thigh infection model, the log area under the 
concentration-vs.-time curve (AUC)/MIC was the 
only parameter predictive of efﬁcacy for the ﬁrst 6 
h, and that peak concentration in itself was not pre-
dictive of efﬁcacy. This might suggest that Garacol 
and Septocoll have equal clinical efﬁcacy, because 
both have bactericidal concentrations within 6 h 
and for the ﬁrst 2 days. 
We conclude that the in vivo release of gentamy-
cin from collagen ﬂeeces in humans differs from 
that of other methods of application—especially 
the high bactericidal concentrations, without any 
risk of serious adverse effects. Gentamycin-loaded 
collagen ﬂeeces may be useful as an adjuvant treat-
ment for implant-related infections.
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